Commentary Open Access
Volume 1 | Issue 4 | DOI: https://doi.org/10.33696/haematology.1.019
Unmasking the Master of Disguise: Defining Advancements in Diagnosis of Intravascular Large B-cell Lymphoma
Matthew Brunner1,*, Luke Zurbriggen1, Julie E. Chang1,2
- 1Carbone Cancer Center, University of Wisconsin Hospital and Clinics, Wisconsin, USA
- 2Department of Medicine, University of Wisconsin School of Medicine & Public Health, Wisconsin, USA
Corresponding Author
Matthew Brunner, Mbrunner2@uwhealth.org
Received Date: October 22, 2020
Accepted Date: December 21, 2020
Brunner M, Zurbriggen L, Chang JE. Unmasking the Master of Disguise: Defining Advancements in Diagnosis of Intravascular large B-cell Lymphoma. J Clin Haematol. 2020; 1(4):125-131.
Copyright: © 2020 Brunner M, et al. This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Keywords
Intravascular lymphoma, Rituximab, Circulating tumor DNA, Hemophagocytosis, Random skin biopsy
Recommended Articles
Chimeric Antigen Receptor CAR NK Cells Emerging Immunotherapy for the Treatment of Cancer
Although NK cells are recognized as effector lymphocytes of the innate immune system, they also regulate the adaptive immune response by releasing inflammatory cytokines and developing immunological memory. Unlike other lymphocytes such as T or B cells, NK cells do not express rearrangeable, antigen-specific receptors.
Angioimmunoblastic T cell Lymphoma Microenvironment
Angioimmunoblastic T cell lymphoma (AITL) is one of the most common T-cell lymphomas, second only to peripheral T-cell lymphoma not otherwise specified (PTCL-NOS). Initially AITL was considered a non-malignant lymphadenopathy with immune hyperactivation, nowadays being classified as a PTCL.
Safety of Using Rituximab Therapy During COVID-19 Pandemic
Our modern world is facing extraordinary circumstances while passing through a serious pandemic caused by the novel coronavirus (COVID-19) which may lead to multi-organ system failure & death. Bcell depletion could compromise antiviral immunity, which makes the safety of rituximab use in the COVID19 era unclear.
Deubiquitinase as Potential Targets for Cancer Immunotherapy
During the last few decades, immunotherapy is considered to be an important approach to help our immune system to fight various kinds of diseases, such as tumor. Sometimes, it works very well for some types of cancers, for example: bladder cancer, colorectal cancer, breast cancer and lymphoma.
Reduced BCR Signaling and a Metabolic Shift Accompanies Malignant Progression of Follicular Lymphoma: A Lesson from Transcriptomics
In the manuscript entitled “The ion channels and transporters gene expression profile indicates a shift in excitability and metabolisms during malignant progression of Follicular Lymphoma”, we reported recent advances in our understanding of how the gene expression profile of ion channels and transporters (ICT-GEP) contributes to identify specific signatures associated with Follicular Lymphoma (FL), with those FL that acquire chemoresistance after a relapsing-remitting course, and with the more aggressive Diffuse Large Cell Lymphoma (DLBCL), which in some cases represent the evolution of FLs.